Issue: Exclusive Online Content, Posted Date: 2/3/2017
Patheon Announces Completion of its Acquisition of State-of-the-Art Manufacturing Site
Patheon N.V (NYSE: PTHN), a leading global provider of
high-quality drug development and delivery solutions to the pharmaceutical and
biopharma sectors, announced that it has completed the acquisition of a
state-of-the-art manufacturing facility in Florence, South Carolina from Roche
Holdings, Inc. Patheon has begun integrating the site into the Patheon network.
site adds a 300,000 square-foot facility with manufacturing capacity for active
pharmaceutical ingredient (API) ranging from development to manufacturing
services. With the addition of this site, the company expands its capacity for
manufacturing highly potent compounds, adds capabilities to support solid state
chemistry, micronization (small & large) and future commercial spray
are extremely pleased to add this facility to the Patheon network and the
talented professionals that will support a wide range of drug substance
services,” said Lukas Utiger, president of Drug Substance Services for Patheon.
“Patheon has extensive experience and success integrating new sites into our
global network and quickly leveraging the capabilities for the benefit of our
new Patheon acquisition is a state-of-the-art pharmaceutical manufacturing
facility. In its production space it features reactors ranging from 50-11,000
liters producing multiple products simultaneously, fully compliant to all
applicable regulations, fully validated to meet the most stringent production,
quality, cGMP (current Good Manufacturing Practices), safety and environmental
standards. The site also provides highly flexible operations allowing the
company to adapt quickly to new production needs and with capabilities in small
and large scale manufacturing.
site will serve as Patheon’s flagship U.S. API operation for commercial scale
and mid-scale API production, and will also enhance Patheon’s emerging pharma
presence in the U.S. market. This acquisition is the sixth in the last five
years and supports the company’s plans to create the only integrated,
end-to-end provider of pharma development and manufacturing services.
is a leading global provider of pharmaceutical development and manufacturing
services. With approximately 8,000 employees worldwide, Patheon provides a
comprehensive, integrated and highly customizable set of solutions to help
clients of all sizes satisfy complex development and manufacturing needs at any
stage of the pharmaceutical development cycle. A Healthier World.
This record has been viewed 285 times.